CV Sciences, Inc. (CVSI) Stock Analysis

CV Sciences, Inc. (CVSI) Healthcare & Pipeline Overview

CV Sciences, Inc. develops and markets hemp-based CBD products and plant-based dietary supplements under brands like PlusCBD, targeting the nutraceutical, beauty, and pet sectors. It also develops cannabinoid-based pharmaceuticals, positioning itself in both the consumer wellness and specialty drug markets within the healthcare industry.

What Is the Investment Thesis for CVSI?

CV Sciences, Inc. presents a speculative investment thesis centered on its dual approach to the cannabinoid market through consumer products and pharmaceutical development. The company's established consumer product lines, generating a gross margin of 47.0%, provide a revenue base to fund its pharmaceutical endeavors. The development of CVSI-007, targeting smokeless tobacco addiction, represents a high-risk, high-reward opportunity. The company's small market capitalization of $3.96M and negative P/E ratio of -4.99 indicate substantial risk. Successful clinical trials and subsequent commercialization of CVSI-007 could drive significant value. However, regulatory hurdles, competition, and the need for additional capital are potential risks. Investors should closely monitor clinical trial outcomes, regulatory developments, and the company's ability to maintain market share in the competitive CBD consumer product market.

Based on FMP financials and quantitative analysis

CVSI Key Highlights

Market capitalization of $3.96M, reflecting its status as a micro-cap company.

• Negative P/E ratio of -4.99, indicating that the company is currently unprofitable.
• Gross margin of 47.0%, showcasing the potential profitability of its consumer product segment.
• Beta of 0.19, suggesting lower volatility compared to the overall market.
• Focus on developing CVSI-007, a pharmaceutical drug candidate for smokeless tobacco addiction, highlighting its commitment to innovation.

Who Are CVSI's Competitors?

CVSI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CVSI's Key Strengths?

Established brand presence in the CBD market.

• Diverse product portfolio across multiple health sectors.
• Dual focus on consumer products and pharmaceutical development.
• Proprietary drug candidate CVSI-007.

What Are CVSI's Weaknesses?

Small market capitalization and limited financial resources.

• Negative profitability and reliance on external funding.
• Dependence on regulatory environment for CBD products.
• Limited market share compared to larger competitors.

What Could Drive CVSI Stock Higher?

Clinical trial results for CVSI-007 in smokeless tobacco addiction treatment.

• Expansion of the PlusCBD product line into new retail channels.
• Development of new CBD-based products for specific health conditions.
• Geographic expansion into international markets.
• Potential strategic acquisitions of complementary businesses.

What Are the Key Risks for CVSI?

Financial-distress signal — its Altman Z-Score of -17.50 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-88.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory changes impacting the CBD market.
• Delays or failures in clinical trials for CVSI-007.
• Intense competition in the CBD market.
• Limited financial resources and reliance on external funding.
• Fluctuations in raw material prices.

What Are the Growth Opportunities for CVSI?

• Expansion of the PlusCBD product line into new retail channels: CV Sciences can expand its reach by securing partnerships with major retail chains and online marketplaces. The global nutraceutical market is projected to reach $441.7 billion by 2026, offering a significant opportunity for increased sales. Timeline: Ongoing.
• Development and commercialization of CVSI-007: Successful clinical trials and regulatory approval of CVSI-007 for smokeless tobacco addiction could create a significant revenue stream. The market for smoking cessation products is estimated at $8.7 billion globally. Timeline: 3-5 years, contingent on clinical trial results and regulatory approvals.
• Geographic expansion into international markets: CV Sciences can explore opportunities to expand its consumer product sales into international markets, particularly in Europe and Asia, where the demand for CBD products is growing. The European CBD market is projected to reach $1.5 billion by 2027. Timeline: 2-3 years.
• Strategic acquisitions of complementary businesses: CV Sciences can consider acquiring smaller companies with innovative products or technologies in the CBD or nutraceutical space to expand its product portfolio and market reach. The M&A activity in the cannabis industry remains active. Timeline: Opportunistic.
• Development of new CBD-based products for specific health conditions: CV Sciences can invest in research and development to create new CBD-based products targeting specific health conditions, such as anxiety, sleep disorders, and pain management. The market for CBD-based health products is expanding rapidly. Timeline: Ongoing.

What Are CVSI's Competitive Advantages?

• Established brand recognition with PlusCBD and other brands.
• Proprietary formulations and manufacturing processes.
• Focus on both consumer products and pharmaceutical development.
• Distribution network through multiple channels.

What Does CVSI Do?

CV Sciences, Inc., established in 2010 and based in San Diego, California, operates as a life science company in North America. Initially known as CannaVest Corp., the company rebranded in January 2016 to reflect its focus on cannabinoid-based products. CV Sciences is structured into two primary segments: Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under various brand names, including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. These products cater to diverse health care sectors, including nutraceuticals, beauty care, specialty foods, and pet products. The company distributes its consumer products through its websites, internet sales channels, select distributors, brick-and-mortar retailers, and e-tailers. The Specialty Pharmaceutical segment is dedicated to the development and commercialization of cannabinoids for treating medical indications. Its lead drug candidate, CVSI-007, combines CBD and nicotine for the treatment of smokeless tobacco use and addiction, representing the company's foray into pharmaceutical applications of cannabinoids. CV Sciences aims to leverage its expertise in both consumer wellness and pharmaceutical development to establish a strong presence in the cannabinoid market.

What Products and Services Does CVSI Offer?

• Develops and markets plant-based dietary supplements.
• Manufactures and sells hemp-based cannabidiol (CBD) products.
• Operates in the nutraceutical, beauty care, specialty foods, and pet product sectors.
• Sells products through websites, internet sales, distributors, retailers, and e-tailers.
• Develops cannabinoid-based pharmaceuticals for medical indications.
• Focuses on CVSI-007, a drug candidate for smokeless tobacco addiction.

How Does CVSI Make Money?

• Develops and manufactures CBD and plant-based products.
• Sells products directly to consumers through online channels.
• Distributes products through retail partnerships.
• Develops pharmaceutical drugs based on cannabinoids.

What Industry Does CVSI Operate In?

CV Sciences operates within the rapidly evolving cannabis and CBD industry. The market is characterized by increasing consumer acceptance of CBD products for wellness applications and growing interest in cannabinoid-based pharmaceuticals. The industry faces regulatory uncertainty and intense competition from both established players and new entrants. CV Sciences' dual focus on consumer products and pharmaceutical development positions it to capitalize on both the immediate demand for CBD products and the long-term potential of cannabinoid-based therapies. Competitors include companies like AUSAF, AYRWF, AYURF, BQST, and BUDZ, all vying for market share in the cannabis and CBD space.

Who Are CVSI's Key Customers?

• Consumers seeking plant-based dietary supplements.
• Individuals interested in hemp-based CBD products for wellness.
• Retailers and distributors in the nutraceutical and beauty industries.
• Patients seeking cannabinoid-based pharmaceuticals (future).

CV Sciences, Inc. Financial Trajectory

CV Sciences, Inc. (CVSI) reported $3.0M in revenue for Q2 FY2026, a decline of 6.6% compared to the prior quarter. The company recorded a net loss of $775K, with diluted EPS of $-0.00. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, CVSI averaged $-0.00 in diluted EPS.

Company Profile

CV Sciences, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Joseph D. Dowling. CVSI has traded publicly since 2013.

How CV Sciences, Inc. Is Valued

CV Sciences, Inc. carries a market capitalization of $3.96M, placing it in the micro-cap category.

Return on equity for CV Sciences, Inc. stands at -88.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -6.9%, showing how much profit it generates from its asset base. A current ratio of 0.96 means current liabilities exceed short-term assets, a liquidity point worth watching.

CV Sciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -17.50 places it in the distress zone, a signal of elevated financial risk.

CV Sciences, Inc. has beaten Wall Street's EPS estimate in 3 of its last 4 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 63.3% above estimates on average.

Over the past six months, CV Sciences, Inc. insiders filed 10 SEC Form 4 transactions — 0 sales and 10 purchases. On net that is roughly 5.7M shares acquired (about $115K) — insiders putting money in tends to read as conviction.

CVSI Financials

CVSI Latest News

CVSI Analyst Consensus

CVSI MoonshotScore

CV Sciences, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources